Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Puma Biotechnology (NASDAQ:PBYI) is the #1 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: B.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 48, which is 21 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 96.98% over the past year, overperforming other healthcare stocks by 192 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -34.35% from Puma Biotechnology's current stock price of $9.14.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bristol Myers Squibb Co (NYSE:BMY) is the #2 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: B, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 23 points higher than the healthcare sector average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 38.3% over the past year, overperforming other healthcare stocks by 134 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $67.90, an upside of 5.93% from Bristol Myers Squibb Co's current stock price of $64.10.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Bristol Myers Squibb Co, 54.55% have issued a Strong Buy rating, 0% have issued a Buy, 45.45% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bausch Health Companies (NYSE:BHC) is the #3 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch Health Companies (NYSE:BHC) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: C.

Bausch Health Companies (NYSE:BHC) has a Due Diligence Score of 6, which is -21 points lower than the healthcare sector average of 27. Although this number is below the industry average, our proven quant model rates BHC as a "A".It passed 2 out of 33 due diligence checks and has weak fundamentals. Bausch Health Companies has seen its stock lose -17.55% over the past year, overperforming other healthcare stocks by 78 percentage points.

Bausch Health Companies has an average 1 year price target of $9.00, an upside of 52.03% from Bausch Health Companies's current stock price of $5.92.

Bausch Health Companies stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Bausch Health Companies, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 80 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Conmed (NYSE:CNMD) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 3.29%. Conmed's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Conmed's dividend has not shown consistent growth over the last 10 years.

Conmed's dividend payout ratio of 10.8% indicates that its dividend yield is sustainable for the long-term.

Ataibeckley (NASDAQ:ATAI) has an annual dividend yield of 91.84%, which is 89 percentage points higher than the healthcare sector average of 3.29%.

Ataibeckley's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 22.39%, which is 19 percentage points higher than the healthcare sector average of 3.29%.

Cumberland Pharmaceuticals's dividend payout ratio of -411% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 1.07% in the last day, and down -0.71% over the last week. Pds Biotechnology was the among the top gainers in the healthcare sector, gaining 35.25% yesterday.

PDS Biotech shares are trading higher. The company announced initial closing of up to $22.3 million PIPE financing.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 225.78% in the past year. It has overperformed other stocks in the healthcare sector by 321 percentage points.

Auna Sa (NYSE:AUNA) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Auna Sa has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Auna Sa's stock has dropped -20.09% in the past year. It has overperformed other stocks in the healthcare sector by 75 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 27.82% in the past year. It has overperformed other stocks in the healthcare sector by 123 percentage points.

59.75% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 30.66% over the next year.

4.52% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.43% of healthcare stocks are rated B (Buy), 47.93% are rated C (Hold), 27.35% are rated D (Sell), and 6.78% are rated F (Strong Sell).